DUSP3

Dual specificity protein phosphatase 3 · P51452 · DUSP3 on Sugi Atlas →

132,601 patent compounds predicted against DUSP3, 106,599 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Oleic Acid (SCHEMBL1138)	1.00	2/20
Oleic Acid (SCHEMBL1139)	1.00	2/20
Erucic Acid (SCHEMBL5987)	1.00	2/20
Erucic Acid (SCHEMBL5988)	1.00	2/20
Erucic Acid (SCHEMBL6297)	1.00	2/20
Elaidic Acid (SCHEMBL6693)	1.00	2/20
Linoleic Acid (SCHEMBL7067)	1.00	2/20
SCHEMBL19452	1.00	2/20
Nervonic Acid (SCHEMBL21103)	1.00	2/20
Nervonic Acid (SCHEMBL21104)	1.00	2/20
Palmitoleic Acid (SCHEMBL33310)	1.00	2/20
Palmitoleic Acid (SCHEMBL33311)	1.00	2/20
Vaccenic Acid (SCHEMBL38907)	1.00	2/20
Vaccenic Acid (SCHEMBL38908)	1.00	2/20
Oleic Acid (SCHEMBL51637)	1.00	2/20
Nervonic Acid (SCHEMBL52329)	1.00	2/20
SCHEMBL52733	1.00	2/20
SCHEMBL52734	1.00	2/20
SCHEMBL53302	1.00	2/20
SCHEMBL53303	1.00	2/20

Clinical trials — most relevant to DUSP3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans	PHASE4	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Semen Analysis Changes in Covid-19 Positivepatients	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP3 binder may also engage these)

Protein	Name	Similarity
Q5RD73	—	1.000	Q5RD73 →
Q9D7X3	—	0.999	Q9D7X3 →
P0C599	—	0.981	P0C599 →
Q4KL92	—	0.980	Q4KL92 →
P0C5A0	—	0.980	P0C5A0 →
Q9JLY7	—	0.979	Q9JLY7 →
Q8BK84	—	0.978	Q8BK84 →
A4IHU7	—	0.978	A4IHU7 →
P0C591	—	0.978	P0C591 →
P0C593	—	0.977	P0C593 →
P0C5A1	—	0.976	P0C5A1 →
Q4RQD3	—	0.976	Q4RQD3 →
P0C597	—	0.975	P0C597 →
P0C598	—	0.975	P0C598 →
Q17QM8	—	0.975	Q17QM8 →
O95147	—	0.974	O95147 →
Q68J44	—	0.973	Q68J44 →
P0C595	—	0.973	P0C595 →
Q29RA3	—	0.973	Q29RA3 →
DUSP22	Dual specificity protein phosphatase 22	0.973	landscape →
Q99N11	—	0.972	Q99N11 →
P0C5A2	—	0.972	P0C5A2 →
P0C596	—	0.970	P0C596 →
P0C594	—	0.970	P0C594 →
P0C592	—	0.968	P0C592 →
Q9H596	—	0.967	Q9H596 →
Q8VE01	—	0.966	Q8VE01 →
Q9M8K7	—	0.966	Q9M8K7 →
Q566R7	—	0.965	Q566R7 →
P28563	—	0.965	P28563 →